6 results match your criteria: "California Dermatology and Clinical Research Institute[Affiliation]"
Article Synopsis
- * In a trial with 120 participants, those treated with the TAT-Patch showed a significant improvement in sweating severity compared to those who received a sham patch, with 64% achieving better results after four weeks.
- * The TAT-Patch led to meaningful reductions in sweat production and improved quality of life, and while some mild side effects were noted, the treatment was generally well tolerated with no serious adverse events.
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Br J Dermatol
July 2023
Pfizer Inc., Cambridge, MA, USA.
Background: Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways.
Objectives: To assess the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase 2/JAK1 inhibitor, in participants with mild-to-moderate PsO.
Methods: This phase IIb multicentre randomized double-blind study was conducted in two stages.
Introduction: This cross-sectional survey was conducted with National Psoriasis Foundation (NPF) to capture treatment perspectives and expectations in patients with psoriasis (PsO) using Patient Needs Questionnaire (PNQ) of Patient Benefit Index (PBI).
Methods: Adult participants with self-reported diagnosis of PsO responded to the PNQ portion of PBI by indicating how much they valued different treatment attributes. All the treatment goals were captured on a five-point Likert scale (0 = "Not important", 4 = "Very important").
Background: Itch and sleep disturbance due to itch are burdensome symptoms associated with atopic dermatitis (AD). Rapid onset of action is important for AD treatments to improve quality of life and relieve suffering.
Objectives: This subanalysis evaluated how quickly baricitinib 1-mg and 2-mg reduced itch and associated sleep disturbance during the first 7 days after treatment initiation in a phase 3, double-blind, placebo-controlled trial.
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
J Am Acad Dermatol
June 2020
Brickell Biotech, Inc, Boulder, Colorado.
Article Synopsis
- Primary axillary hyperhidrosis has few effective noninvasive treatments, prompting a study on sofpironium bromide as a topical solution.
- A phase II trial involved participants receiving daily treatment over 42 days, assessing improvement in sweat severity using the HDSM-Ax score.
- Results showed significant improvement in sweat severity for those using sofpironium bromide compared to a placebo, with most side effects being mild to moderate.